RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO) IN THE TREATMENT OF ANEMIA ASSOCIATED WITH SOLID TUMORS WITH OR WITHOUT BONE-MARROW INFILTRATION

  • Authors:
    • E BAJETTA
    • M DIBARTOLOMFO
    • R BUZZONI
    • AM BOCHICCHIO
    • M COLLEONI
  • View Affiliations

  • Published online on: December 1, 1993     https://doi.org/10.3892/ijo.3.6.1121
  • Pages: 1121-1126
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

This study was designed to test the efficacy of rHuEPO in inducing an increase of at least 2 gr/dl over baseline hemoglobin levels in patients affected by solid tumors, with or without bone marrow invasion. The treatment plan consisted of the administration of rHuEPO 150 U/kg of body weight 3 times/week for 6 weeks. In responding patients, a maintenance schedule of 150 U/kg/week was given for a further 6 weeks. Twenty patients with hemoglobin levels of between 8 and 10 gr/dl were treated, 10 of whom (50%) had bone marrow infiltration. There was a significant difference between median baseline serum EPO levels in patients with and without bone marrow invasion (123.5 vs 40 mU/ml, p=0.002). A response was achieved in 10 of the 20 cases (50%), the median duration being 14 weeks (range 3-34+). Three of the 10 patients with bone marrow involvement responded to treatment, as opposed to 7 without bone marrow invasion (30% vs 70%; p=0.179). The treatment was well tolerated and did not give rise to any severe side effects, These data suggest that the rHuEPO 150 U/kg 3 times/wk controls chronic anemia in 50% of patients affected by solid tumors. Good efficacy of rHuEPO treatment was observed in patients without bone marrow infiltration.

Related Articles

Journal Cover

December 1993
Volume 3 Issue 6

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
BAJETTA E, DIBARTOLOMFO M, BUZZONI R, BOCHICCHIO A and COLLEONI M: RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO) IN THE TREATMENT OF ANEMIA ASSOCIATED WITH SOLID TUMORS WITH OR WITHOUT BONE-MARROW INFILTRATION. Int J Oncol 3: 1121-1126, 1993.
APA
BAJETTA, E., DIBARTOLOMFO, M., BUZZONI, R., BOCHICCHIO, A., & COLLEONI, M. (1993). RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO) IN THE TREATMENT OF ANEMIA ASSOCIATED WITH SOLID TUMORS WITH OR WITHOUT BONE-MARROW INFILTRATION. International Journal of Oncology, 3, 1121-1126. https://doi.org/10.3892/ijo.3.6.1121
MLA
BAJETTA, E., DIBARTOLOMFO, M., BUZZONI, R., BOCHICCHIO, A., COLLEONI, M."RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO) IN THE TREATMENT OF ANEMIA ASSOCIATED WITH SOLID TUMORS WITH OR WITHOUT BONE-MARROW INFILTRATION". International Journal of Oncology 3.6 (1993): 1121-1126.
Chicago
BAJETTA, E., DIBARTOLOMFO, M., BUZZONI, R., BOCHICCHIO, A., COLLEONI, M."RECOMBINANT-HUMAN-ERYTHROPOIETIN (RHUEPO) IN THE TREATMENT OF ANEMIA ASSOCIATED WITH SOLID TUMORS WITH OR WITHOUT BONE-MARROW INFILTRATION". International Journal of Oncology 3, no. 6 (1993): 1121-1126. https://doi.org/10.3892/ijo.3.6.1121